Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal year 2022 ended December 31, 2021 before financial markets open on February 9, 2022. READ MORE: https://finance.yahoo.com/news/canopy-growth-report-third-quarter-120000963.html?.tsrc=rss
Week in Weed: Canadian serial entrepreneur Bruce Linton is unapologetically blunt, China’s ancient taste for cannabis, and is this the first U.S. senate race ad featuring pot? The Special Access Program by Health Canada was launched last week, giving Canadians access to restricted drugs and psychedelics treatments. But before anyone celebrates, there’s a catch. The access is for emergency treatments and…
Canopy Growth pushed back its profitability targets and its market share has slipped. So is there any reason to buy CGC stock now? READ MORE: https://finance.yahoo.com/m/a72862de-cc5e-3ff8-aa5d-7e9bc39a83f6/any-reason-to-buy-canopy.html?.tsrc=rss
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) today announced the release of its Environmental, Social, and Governance (ESG) Report (“the Report”) for calendar year 2020, as well as qualitative details on some key activities that occurred in 2021. The Report recognizes Canopy’s current progress and describes its priorities and approach to ESG as part of…
You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve as well as links to the week’s most important news. Subscribe to receive our free weekly newsletter in […] READ MORE: https://www.newcannabisventures.com/constellation-brands-has-gone-from-fomo-to-frustration-with-its-canopy-growth-investment/
Analyst Michael Lavery downgrades the stock to Underweight from Neutral, and also lowers his price target to $7 from $11. READ MORE: https://finance.yahoo.com/m/5a871de5-a74b-3968-b624-dd930c212da2/canopy-growth-is-downgraded.html?.tsrc=rss
Canopy Growth Divests German Pharmaceutical Subsidiary at Massive Discount to 2019 Acquisition Price
Canopy Growth Divests Pharmaceutical C3 Cannabinoid Compound Company Sale supports the Company’s strategic focus on driving demand for cannabis and cannabinoid-based consumer products SMITHS FALLS, ON and NEUMARKT-IN-DER-OBERPFALZ, Germany, Dec. 15, 2021 /PRNewswire/ – Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) has entered into an agreement to divest its subsidiary business, C3 Cannabinoid Compound Company […] READ MORE: https://www.newcannabisventures.com/canopy-growth-divests-german-pharmaceutical-subsidiary-at-massive-discount-to-2019-acquisition-price/
Canopy Growth Corp. said Wednesday it agreed to sell its Cannabinoid Compound Company GmbH (C3) to Dermapharm Holding SE for up to 122.6 million euros ($138 million). Canopy Growth said the transaction will reduce its short-term capital investment requirements by more than $38.9 million. Shares of Canopy Growth rose 1% in pre-market trades. READ MORE: https://finance.yahoo.com/m/52cd3c70-e9f0-326e-a79b-8c91b73cb8c4/canopy-growth-corp-sells.html?.tsrc=rss
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) has entered into an agreement to divest its subsidiary business, C³ Cannabinoid Compound Company GmbH (“C3”), to Dermapharm Holding SE (“Dermapharm”) (WKN: A2GS5D, ISIN: DE000A2GS5D8), a European pharmaceutical company headquartered in Grünwald, Germany. The C³ business develops and manufactures pharmaceutical products and is comprised of Spectrum Therapeutics GmbH,…
Investment company USA Mutuals Vice Fund (Current Portfolio) buys Canopy Growth Corp, sells Vanguard FTSE All-World ex-US ETF, Alibaba Group Holding, Direxion Russell 1000 Value Over Growth ETF, iShares MSCI United Kingdom ETF, ViacomCBS Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, USA Mutuals Vice Fund. READ MORE: https://finance.yahoo.com/news/usa-mutuals-vice-fund-buys-183804411.html?.tsrc=rss
Analysts at investment bank Wells Fargo initiated coverage across the sector, warning of overvaluation among marijuana companies and suggesting investors turn their attention to hydroponics suppliers instead — but marijuana stocks leapt higher anyway. As of 12:35 p.m. ET, shares of Tilray (NASDAQ: TLRY) are gaining 4.6%, and both Aurora Cannabis (NASDAQ: ACB) and Canopy Growth (NASDAQ: CGC) are up…
U.S. legalization is still stalled, but Mexican marijuana legalization could be imminent. READ MORE: https://finance.yahoo.com/m/65dcbc39-8766-3994-9fd0-ee8da9955412/why-aurora-cannabis%2C-canopy.html?.tsrc=rss